Close Menu

miRNA

The firm launched three microRNA-based tests during the fourth quarter, and posted a profit due to a capital gain on the sale of Auction Rate Securities to Credit Suisse. However, Rosetta only has enough cash to fund operations through mid-2010 and said that it may seek to raise additional funds.

An Affy spokesperson said the firm's interest in the market is an extension of its gene-expression profiling play, and said several "key advantages" over rival tools could enable it to profit in the market, which is poised to grow 25 percent through 2015.

An Italian research team demonstrated that miR-9 is up-regulated in two types of human immune cells during the pro-inflammatory process and may regulate a NF-kappa-B subunit.

Strands: Mar 12, 2009

Premium

Rosetta Genomics, Alnylam Pharmaceuticals, Massachusetts Institute of Technology

The company is looking to differentiate itself from other players in the miRNA array market — such as Agilent Technologies, Life Technologies, Exiqon, and Febit — by stressing the "quality, performance, and affordability" of its OneArray platform.

The firm published data from a study showing that the same biomarker used in its miRNA-based test for squamous lung cancer provided 96 percent sensitivity.

Pages

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.